Chronic Kidney Disease
The Pharmacy Times® Chronic Kidney Disease resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.
Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.
Ferric citrate was originally approved for the control of serum phosphorus levels in patients with chronic kidney disease who require dialysis.
An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.
Patients with chronic kidney disease are at risk for several comorbid conditions, including cardiovascular disease.
Patients who develop chronic kidney disease (CKD) are at risk for a number of comorbidities, including cardiovascular decline.
Women with the hepatitis C virus have fewer live births and face a higher risk of miscarriage, infertility, gestational diabetes and pre-eclampsia.
Patients with stage 3 kidney disease cured of hepatitis C virus experienced an improvement in kidney function following treatment.
Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.
Results from the EMPA-REG OUTCOME trial suggests empagliflozin (Jardiance) has potential in the treatment of chronic kidney disease.
Epoetin alfa biosimilar has indications in cancer, HIV, and chronic kidney disease, among other conditions.